{"doi":"10.1038/psp.2013.59","title":"Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated <i>Plasmodium falciparum</i> Malaria in Uganda","abstract":"<jats:p>Pregnancy alters the pharmacokinetic properties of many antimalarial compounds. The objective of this study was to evaluate the pharmacokinetic properties of lumefantrine in pregnant and nonpregnant women with uncomplicated <jats:italic>Plasmodium falciparum</jats:italic> malaria in Uganda after a standard fixed oral artemether–lumefantrine treatment. Dense venous (<jats:italic>n</jats:italic> = 26) and sparse capillary (<jats:italic>n</jats:italic> = 90) lumefantrine samples were drawn from pregnant patients. A total of 17 nonpregnant women contributed with dense venous lumefantrine samples. Lumefantrine pharmacokinetics was best described by a flexible absorption model with multiphasic disposition. Pregnancy and body temperature had a significant impact on the pharmacokinetic properties of lumefantrine. Simulations from the final model indicated 27% lower day 7 concentrations in pregnant women compared with nonpregnant women and a decreased median time of 0.92 and 0.42 days above previously defined critical concentration cutoff values (280 and 175 ng/ml, respectively). The standard artemether–lumefantrine dose regimen in <jats:italic>P. falciparum</jats:italic> malaria may need reevaluation in nonimmune pregnant women.</jats:p><jats:p><jats:italic>CPT: Pharmacometrics &amp; Systems Pharmacology</jats:italic> (2013) 2, e83; doi:<jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038/psp.2013.59\">10.1038/psp.2013.59</jats:ext-link>; advance online publication 13 November 2013</jats:p>","journal":"CPT: Pharmacometrics &amp; Systems Pharmacology","year":2013,"id":673347,"datarank":0.5775221402565088,"base_score":3.8501476017100584,"endowment":3.8501476017100584,"self_citation_contribution":0.5775221402565088,"citation_network_contribution":0.0,"self_endowment_contribution":0.5775221402565088,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":46,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1759249,"name":"P Piola","orcid":null,"position":1,"is_corresponding":false},{"id":1759250,"name":"M Dhorda","orcid":null,"position":2,"is_corresponding":false},{"id":1759251,"name":"S Muwanga","orcid":null,"position":3,"is_corresponding":false},{"id":1759252,"name":"E Turyakira","orcid":null,"position":4,"is_corresponding":false},{"id":1759253,"name":"S Apinan","orcid":null,"position":5,"is_corresponding":false},{"id":1759254,"name":"N Lindegårdh","orcid":null,"position":6,"is_corresponding":false},{"id":1759255,"name":"F Nosten","orcid":null,"position":7,"is_corresponding":false},{"id":1759256,"name":"NPJ Day","orcid":null,"position":8,"is_corresponding":false},{"id":1759257,"name":"NJ White","orcid":null,"position":9,"is_corresponding":false},{"id":1759258,"name":"PJ Guerin","orcid":null,"position":10,"is_corresponding":false},{"id":1759259,"name":"J Tarning","orcid":null,"position":11,"is_corresponding":false},{"id":1759248,"name":"F Kloprogge","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated <i>Plasmodium falciparum</i> Malaria in Uganda","abstract":"<jats:p>Pregnancy alters the pharmacokinetic properties of many antimalarial compounds. The objective of this study was to evaluate the pharmacokinetic properties of lumefantrine in pregnant and nonpregnant women with uncomplicated <jats:italic>Plasmodium falciparum</jats:italic> malaria in Uganda after a standard fixed oral artemether–lumefantrine treatment. Dense venous (<jats:italic>n</jats:italic> = 26) and sparse capillary (<jats:italic>n</jats:italic> = 90) lumefantrine samples were drawn from pregnant patients. A total of 17 nonpregnant women contributed with dense venous lumefantrine samples. Lumefantrine pharmacokinetics was best described by a flexible absorption model with multiphasic disposition. Pregnancy and body temperature had a significant impact on the pharmacokinetic properties of lumefantrine. Simulations from the final model indicated 27% lower day 7 concentrations in pregnant women compared with nonpregnant women and a decreased median time of 0.92 and 0.42 days above previously defined critical concentration cutoff values (280 and 175 ng/ml, respectively). The standard artemether–lumefantrine dose regimen in <jats:italic>P. falciparum</jats:italic> malaria may need reevaluation in nonimmune pregnant women.</jats:p><jats:p><jats:italic>CPT: Pharmacometrics &amp; Systems Pharmacology</jats:italic> (2013) 2, e83; doi:<jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038/psp.2013.59\">10.1038/psp.2013.59</jats:ext-link>; advance online publication 13 November 2013</jats:p>","is_dataset_classified":null,"base_score":3.8501476017100584,"endowment":3.8501476017100584,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"24226803","pmcid":"PMC3852159","openalex_id":"https://openalex.org/W1983547056","authors":[],"funders":[{"funder_name":"Wellcome Trust","grant_id":"089275","title":null},{"funder_name":"Wellcome Trust","grant_id":"093956/Z/10/Z","title":null},{"funder_name":"Wellcome Trust","grant_id":"093956","title":null},{"funder_name":"Wellcome Trust","grant_id":"unidentified","title":"unidentified"}],"total_grants":4,"fwci":3.5115,"citation_percentile":0.91775446,"influential_citations":0,"citation_trend":[{"year":2014,"count":2},{"year":2015,"count":3},{"year":2016,"count":6},{"year":2017,"count":5},{"year":2018,"count":6},{"year":2019,"count":5},{"year":2020,"count":5},{"year":2021,"count":6},{"year":2022,"count":3},{"year":2023,"count":1},{"year":2024,"count":2},{"year":2025,"count":1},{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by-nc-nd","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1038/psp.2013.59","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1038/psp.2013.59","host_type":"publisher"},{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1038%2Fpsp.2013.59","host_type":"publisher"},{"url":"https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1038/psp.2013.59","host_type":"publisher"},{"url":"https://doi.org/10.1038/psp.2013.59","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/24226803","host_type":"repository"},{"url":"http://europepmc.org/articles/PMC3852159","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3852159","host_type":"repository"},{"url":"http://fieldresearch.msf.org/msf/handle/10144/311960","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC3852159","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC3852159?pdf=render","host_type":"Europe_PMC"},{"url":"https://ascpt.onlinelibrary.wiley.com/doi/pdfdirect/10.1038/psp.2013.59","host_type":""},{"url":"http://dx.doi.org/10.1038/psp.2013.59","host_type":""},{"url":"https://dx.doi.org/10.1038/psp.2013.59","host_type":""},{"url":"https://ora.ox.ac.uk/objects/uuid:bae9c035-f799-41f2-a1fc-0013105cc304","host_type":""}],"fields_of_study":["Malaria Research and Control","Drug-Induced Hepatotoxicity and Protection","Drug Transport and Resistance Mechanisms","03 medical and health sciences","0302 clinical medicine"],"mesh_terms":[],"keywords":["Lumefantrine","Artemether/lumefantrine","Pharmacokinetics","Medicine","Malaria","Plasmodium falciparum","Regimen","Obstetrics","Artemether","Pregnancy","Population","Internal medicine","Pharmacology","Artemisinin","Immunology","Biology","Environmental health","Original Article"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-16T13:08:19.286855Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}